428 filings
Page 6 of 22
S-8
ynjdgpi1ltimfxg08t
19 Jan 21
Registration of securities for employees
12:00am
8-K
rj0g0afc53tb4yflykp
5 Jan 21
Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
9:36am
8-K
6r0l 36dlvbq
29 Dec 20
Other Events
4:24pm
8-K
ro0hzrp
22 Dec 20
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
8:34am
8-K
2luft bef
10 Dec 20
Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH
11:32am
8-K
7uhxujn843qik52l
2 Dec 20
Other Events
8:12am
8-K
8dcu81xnc e3
27 Nov 20
Hepion Pharmaceuticals Prices Public Offering
1:48pm
424B4
84qi4nuqiv1qe 7d
25 Nov 20
Prospectus supplement with pricing info
4:28pm
EFFECT
9y6rg huffg
25 Nov 20
Notice of effectiveness
12:15am
8-K
ap7fo9gjwg9w2
20 Nov 20
Termination of a Material Definitive Agreement
4:05pm
CORRESP
1lc6nk16 72yks70a
20 Nov 20
Correspondence with SEC
12:00am
CORRESP
e231pli9
20 Nov 20
Correspondence with SEC
12:00am
FWP
vj9c8k
18 Nov 20
Free writing prospectus
5:29pm
8-K
ifru faodymoa
18 Nov 20
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation of Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
8:29am
8-K
nlldd3o97b ktj1
17 Nov 20
Hepion Pharmaceuticals to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium
4:53pm
FWP
sxovqn
12 Nov 20
Free writing prospectus
5:27pm